Recent Developments
· It is estimated that between 2.7 million and 6.1 million people in the United States have AFib. As the U.S. population ages, this number is expected to increase, according to centre for disease control and prevention. Also, People of European descent are more likely to have AFib than African Americans. In addition to this, as the number of AFib cases increases with age and women generally live longer than men, more women than men experience AFib. These facts point towards the seriousness of the problem and also indicate towards the upcoming rise in the demand for the healthcare support.
· In 2018, Boston Scientific has agreed to pay $202 million in cash to acquire Cryterion Medical, a privately held company developing a cryoablation treatment for atrial fibrillation. The medical device giant has been an investor in Carlsbad, Calif.-based Cryterion since 2016 and the pact hands it the roughly 65 percent remaining stake it does not already own.
“Try a Free Sample Report” Click the link below:
www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry/request/rs1
· In May 2020, Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation. Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH SF Ablation Catheter, evaluated in the PRECEPT study for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent). This PRECEPT study data support a Premarket Approval supplement application to the U.S. Food and Drug Administration.
· In February 2020, Rhythm AI agrees a research collaboration with Israel’s Biosense Webster. The company is the creator of an AI-driven technology identifies sources or drivers of atrial fibrillation (irregular and often abnormally fast heart rate) from information acquired by 3D mapping equipment. The deal grants the former access to data from the latter’s CARTO3 advanced cardiac mapping system to support a multi-centre clinical trial of Rhythm’s STAR Mapping system. With good projection and result in the 1st go, this partnership is bound to create some gem for the benefit of the market.
· In August 2019, AtriCure, Inc, a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management announced that it completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions. This acquisition will be extremely beneficial for the company, leading to increased revenue generation and more innovation potential.
· In May 2020, CardioFocus, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). The HeartLight X3 System introduces a new level of speed, control and predictability for physicians — making it an ideal tool for AFib ablation. FDA approval of the HeartLight X3 System represents a substantial milestone for CardioFocus and is a promising new treatment option for the millions of Americans suffering from paroxysmal AFib
· In March 2019, Boston Scientific announced positive data from clinical trial for balloon catheter. It announced positive safety and efficacy results with the Luminize Radiofrequency (RF) Balloon Catheter for isolation of pulmonary veins (PV) when treating patients with atrial fibrillation (AF) at a clinical trial session at EHRA 2019. By providing real-time visualisation both before and during ablation and individualised control of electrode energy levels, this technology may allow physicians to swiftly and accurately isolate veins and decrease procedure times.
